Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple Turns 50: From Garage Startup to AI Crossroads 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
BOSTON, Sept. 05, 2017 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast corporate presentations at the following investor conferences in September:
- A fireside chat at Morgan Stanley’s Global Healthcare Conference in New York City on Tuesday, September 12, 2017 at 12:55 p.m. EDT.
- Cantor Fitzgerald’s Global Healthcare Conference in New York City on Monday, September 25, 2017 at 4:45 p.m. EDT.
- Ladenburg Thalmann’s 2017 Healthcare Conference in New York City on Tuesday, September 26 at 11:30 a.m. EDT.
Live audio webcasts of the presentations will be accessible from Keryx Biopharmaceuticals’ website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentations.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with kidney disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617-466-3511 [email protected]
